Immutep Limited (FRA:YP1B)

Market Cap	42.83M -80.9%
Revenue (ttm)	4.50M +62.4%
Net Income	-47.67M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0260
Previous Close	0.0190
Day's Range	0.0260 - 0.0260
52-Week Range	0.0060 - 0.2500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 29, 2026

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YP1B

Financial Performance

In fiscal year 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error